Last week, we had the privilege of joining Andrew Hopkins (founder of Exscientia and now Xyme) and Jared Saul, MD Saul (Chief Medical Officer at AWS) for a fireside chat hosted by Averin Capital. The key theme that emerged was "AI is not just a research tool – it's decision maker now".
BIOPTIC is designed to operate as AI-native autonomous biopharma — capable of blending investment, scientific, and regulatory decisions using a unified reinforcement learning loop. We're not just helping scientists design molecules; we're connecting the dots between science, business, and regulation to turn research into molecules, molecules into approved drugs, and drugs into ROI.
Machine learning has progressed from Prediction → Perception → Generation → Reasoning → Agency. Most AIDD companies focus on Generation (of new molecules) . We’re building a complete Vertical Agentic AI platform for Biopharma — a system that not only generate outputs, but plans, reasons, and even writes their own code to pursue drug development goals.
The future of drug development isn’t a pipeline of handoffs. It’s a closed loop — an intelligent, iterative engine that learns, decides, and improves. That’s our vision at Bioptic. And it’s energizing to see others pushing in the same direction.
